AU Patent

AU2022203969A1 — Selective Estrogen Receptor Degraders

Assigned to Eli Lilly and Co · Expires 2022-06-30 · 4y expired

What this patent protects

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R' or R2 is independently selected from Cl, F, -CF 3, or - CH3, and the other is hydrogen, and meth…

USPTO Abstract

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R' or R2 is independently selected from Cl, F, -CF 3, or - CH3, and the other is hydrogen, and methods for their use are provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022203969A1
Jurisdiction
AU
Classification
—
Expires
2022-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.